1. ALLA AKTIER
  2. NYHETER
  3. NEWBURY PHARMACEUTICALS

Newbury Pharmaceuticals

Nyheter Newbury Pharmaceuticals Nyheter alla bolag

Strong Quarterly Sales Announcement from Newbury Pharmaceuticals

MAR

Newbury Pharmaceuticals AB is pleased to announce higher than expected sales growth in Quarter 4 (June-Aug 2024) reaching sales of approximately 20 MSEK for the period.

Sales in the Nordics reached approximately 11 MSEK while international sales reached approximately 9 MSEK. The combination of strong sales in both segments is a result of more products having been launched in the Nordics, as well as a large international sales order, announced earlier this year, having been delivered.

“We are extremely pleased to announce such strong sales uptake which is a combination of a large international sales order and the result of an excellent launch of a new product in the Nordics resulting in a strong uptake. We will continue to pursue such opportunities while we acknowledge that tender sales by nature will fluctuate over time.” says Mr Lars Minor CEO of Newbury.

The figures are preliminary and have not yet been audited by the company's auditor. The full year-end report will be released on 23rd October 2024.

For more information, contact:

Lars Minor, CEO
lars.minor@newburypharma.com
Mobile: +46 72-377 3005

www.newburypharma.com

About Newbury Pharmaceuticals

Newbury Pharmaceuticals is building a pipeline of proprietary and licensed products with focus on specialty and branded products in the Nordics. Newbury aims to make a difference by offering treatment solutions within areas like oncology, rare diseases and neurology. The portfolio is built by leveraging experience and extensive international network. Newbury offers strategic partnerships of innovation for the benefit of the Nordic healthcare market.

Västra Hamnen Corporate Finance is the Company's Certified Adviser on Nasdaq First North and can be reached at ca@vhcorp.se or +46 (0) 40 200 250.

This information is information that Newbury Pharmaceuticals is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-09-27 15:56 CEST.

Attachments

Strong Quarterly Sales Announcement from Newbury Pharmaceuticals

Datum 2024-09-27, kl 15:56
Källa MFN
Bifogade filer
Strong Quarterly Sales Announcement from Newbury Pharmaceuticals
Affiliate
Alla Aktier tipsar: Har du redan ett konto på Avanza? Varför inte skapa ett på Nordnet också och jämföra funktioner, courtage mm. Det tar inte lång tid, du fixar det direkt här med BankID
Investeringar i värdepapper och fonder innebär alltid en risk och det är inte säkert att du får tillbaka det investerade kapitalet